



Patent

Case No.: 54563US011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:

RICE, MICHAEL J.

Application No.:

10/624419

Group Art Unit:

Unknown

Filed:

July 22, 2003

Examiner:

Unknown

Title:

DYE LABELED IMIDAZOQUINOLINE COMPOUNDS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 **CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents,

P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date

Signed by: Renee A. Wolff

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. Copies of any cited foreign patents, non-patent literature, and unpublished US application documents are enclosed. Pursuant to the waiver in the Pre-OG Notice, dated July 25, 2003, copies of US patents and published US patent applications are no longer required and are not enclosed. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

It is believed that no fee is due; however, in the event a fee is required, please charge the fee to Deposit Account No. 13-3723.

Respectfully submitted,

By: Dean A. Ersfeld, Reg. No.:

Telephone No.: (651) 733-7830

Office of Intellectual Property Counsel 3M Innovative Properties Company Facsimile No.: 651-736-3833

Substitute for form 1449A/PTO (modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

e as many sheets as necessary)

Page 1 of 4

Application Number	10/624,419		
Filing Date	July 22, 2003		
First Named Inventor	Michael J. Rice		
Art Unit			
Examiner Name	Unknown		
Attorney Case Number	54563US011		

			U.S. Patent	Documents	
Exam. Cite Document Number Publication Date or Issue Date Init.* No. Doc. Number-(Kind Code if Known) MM-DD-XXXX or Applicant of Cited Docu					Pages, Columns, Lines, Where
init."	<u> </u>	Doc. Number-(Kind Code if Known)	MM-DD-YYYY	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	A1	US- 3,314,941	04-18-1967	Littell et al.	
	A2	US- 3,917,624	11-04-1975	El-Haj et al.	
	A3	US- 4,689,338	08-25-1987	John F. Gerster	
	A4	US- 4,698,348	10-06-1987	John F. Gerster	
	A5	US- 4,774,339	09-27-1988	Haugland et al.	
	A6	US- 4,929,624	05-29-1990	Gerster et al.	
	A7	US- 4,988,815	01-29-1991	Andre et al.	
	A8	US- 5,037,986	08-06-1991	John F. Gerster	
	A9	US- 5,175,296	12-29-1992	Gerster	
	A10	US- 5,187,288	02-16-1993	Kang et al.	
	A11	US- 5,238,944	08-24-1993	Wick et al.	
	A12	US- 5,248,782	09-28-1993	Haugland et al.	
	A13	US- 5,266,575	11-30-1993	John F. Gerster	
	A14	US- 5,268,376	12-07-1993	John F. Gerster	
	A15	US- 5,274,113	12-28-1993	Kang et al.	
	A16	US- 5,346,905	09-13-1994	John F. Gerster	
	A17	US- 5,352,784	10-04-1994	Nikolaides et al.	
	A18	US- 5,367,076	11-22-1994	Gerster	
	A19	US- 5,389,640	02-14-1995	Gerster et al.	
	A20	US- 5,395,937	03-07-1995	Nikolaides et al.	
	A21	US- 5,446,153	08-29-1995	Llindstrom et al.	
	A22	US- 5,482,936	01-09-1996	Kyle J. Lindstrom	
	A23	US- 5,693,811	12-02-1997	Lindstrom	
	A24	US- 5,741,908	04-21-1998	Gerster et al.	
	A25	US- 5,756,747	05-26-1998	Gerster et al.	
	A26	US- 5,939,090	08-17-1999	Beaurline et al.	
	A27	US- 6,039,969	03-21-2000	Tomai et al.	
	A28	US- 6,069,149	05-30-2000	Nanba et al.	

*Examiner:

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/624,419

Filing Dat July 22, 2003

First Named Inventor Michael J. Rice

Art Unit

Examiner Name Unknown

Attorney Case Number 54563US011

(Use as many sheets as necessary)

Page 2 of 4

ATEN	U.S. Patent Documents						
Exam.	Cite	Document Number	Publication Date or Issue Date	Name of Patentee	Pages, Columns, Lines, Where		
	No.	Doc. Number-(Kind Code if Known)	MM-DD-YYYY	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
	A29	US- 6,083,505	07-04-2000	Miller et al.			
	A30	US- 6,110,929	08-29-2000	Gerster et al.			
	A31	US- 6,194,425	02-27-2001	Gerster et al.			
·	A32	US- 6,245,776	06-12-2002	Skwierczynski et al.			
	A33	US- 6,331,539	12-18-2001	Crooks et al.			
	A34	US- 6,376,669	04-23-2002	Rice et al.			
	A35	US- 2002/0055517 A1	05-09-2002	Smith			
	A36	US- 2002/0058674 A1	05-16-2002	Hedenstrom et al.			
	A37	US- 6,451,810	09-17-2002	Coleman et al.			
	A38	US- 6,518,265	02-11-2003	Kato et al.			
	A39	US- 6,525,064	02-25-2003	Dellaria et al.			
	A40	US- 6,541,485	04-01-2003	Crooks et al.			
	A41	US- 6,545,016	04-08-2003	Dellaria et al.			
	A42	US- 6,545,017	04-08-2003	Dellaria et al.			
	A43	US- 6,558,951	05-06-2003	Tomai et al.			
	A44	US- 6,573,273	06-03-2003	Crooks et al			

	·		Fo	oreign Patent	Documents		
	Cite	For	eign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	Translation
Init.*	No.	Ctry. Code	Number-KindCode (If known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	(Check if yes)
	B1	PCT	WO 01/74343	10-11-2001			
	B2	PCT	WO 02/36592	05-10-2002			X
	В3	PCT	WO 02/46188	06-13-2002			
	B4	PCT	WO 02/46189	06-13-2002			
	B5	PCT	WO 02/46190	06-13-2002			
	В6	PCT	WO 02/46191	06-13-2002			
	B7	PCT	WO 02/46192	06-13-2002			
	B8	PCT	WO 02/46193	06-13-2002			
	B9	PCT	WO 02/46749	06-13-2002			

*	F	y a	m	i	n	ar.

Date C nsidered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (modified)

OCT 2 0 2033

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Page 3 of 4

Application Number	10/624,419		
Filing Date	July 22, 2003		
First Named Inventor	Michael J. Rice		
Art Unit			
Examiner Name	Unknown		
Attorney Case Number	54563US011		

	T& TAIL		Fe	oreign Patent	Documents		
	Cite	For	eign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	Translation
	No.	Ctry. Code	Number-KindCode (If known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	(Check if yes)
	B10	PCT WO 02/102377		12-27-2002			
	B11	PCT	WO 03/020889	03-13-2003			
	B12	PCT	WO 03/043572	05-30-2003			
	B13	PCT	WO 03/045391	06-05-2003			
	B14	JP	9-208584	08-12-1997			
	B15	JP	9-255926	03-26-1999			Х
	B16	JP	11-222432	08-17-1999			Х
	B17	JP	2000-247884 (abs)	09-12-2000			Х
	B18	EP	0 394 026	10-24-1990			
	B19	EP	1 104 764	06-06-2001			

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
	C1	Wozniak, et al, "The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate ^{1,2} . A New and Convenient Amination Method.", <u>Journal of the Royal Netherlands Chemical Society</u> , 102, pp 511-513, December 12, 1983.						
	C2	Brennan, et al, "Automated Bioassay of Interferons in Micro-test Plates", <u>Biotechniques</u> , June/July, 78, 1983.						
	С3	Testerman, et al., "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", <u>Journal of Leukocyte Biology</u> , Volume 58, pp. 365-372, September 1995.						
	C4	Bachman, et al, "Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline", J. Org. Chem, 15, pp 1278-1284 (1950).						
	C5	Jain, et al, "Chemical and Pharmacological Investigations of Some ω-Substituted Alkylamino-3-aminopyridines", J. Med. Chem., 11, pp 87-92 (1968).						
	C6	Baranov, et al., <u>Chem. Abs.</u> 85, 94362, (1976).						
	C7 Berényi, et al, "Ring Transformation of Condensed Dihydro-as-triazines", <u>J. Heterocyclic C</u> pp 1537-1540 (1981).							
	C8	Chollet, et al, "Development of a Topically Active Imiquimod Formulation", Pharmaceutical Development and Technology, 4(1), pp 35-43 (1999)						
	C9	lzumi, et al., "1 <i>H</i> -Imidazo[4,5- <i>c</i>]quinoline Derivatives as Novel Potent TNF-α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1 <i>H</i> -imidazo[4,5- <i>c</i>]pyridines", Bioorganic & Medicinal Chemistry, 11, pp 2541-2550 (2003)						

*E	A 0	 	•	Ι.
_		 •••	-	

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (modified) **Application Number** 10/624,419 **Filing Date** July 22, 2003 **INFORMATION DISCLOSURE First Named Inventor** STATEMENT BY APPLICANT Michael J. Rice Art Unit (e as many sheets as necessary) **Examiner Name** Unknown OCT 2 0 2003

CATERITY		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS
Exam. Init,*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	C10	Gibson et al. "Cellular Requirements for Cytokine Production in Response to the Immunomodulators Imiquimod and S-27609", Journal of Interferon and Cytokine Research, 15, 537-545 (1995).

Attorney Case Number

54563US011

Page 4 of 4

	X				

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.